Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Uchida, Naoya  [Clear All Filters]
Journal Article
Uchida N, R Weitzel P, Shvygin A, Skala LP, Raines L, Bonifacino AC, Krouse AE, Metzger ME, Donahue RE, Tisdale JF. Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model. Mol Ther Methods Clin Dev. 2016;3:16059.
Tamaoki N, Siebert S, Maeda T, Ha N-H, Good ML, Huang Y, Vodnala SK, Haro-Mora JJ, Uchida N, Tisdale JF, et al. Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells. Cell Rep Methods. 2023;3(4):100460.
Ruiz JPablo, Chen G, Mora JJesus Haro, Keyvanfar K, Liu C, Zou J, Beers J, Bloomer H, Qanash H, Uchida N, et al. Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system. Stem Cell Res. 2019;41:101600.
Shin T-H, Zhou Y, Chen S, Cordes S, Grice MZ, Fan X, Lee B-C, AlJanahi AA, Hong SGun, Vaughan KL, et al. Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions. Blood. 2022.
Drysdale CM, Nassehi T, Gamer J, Yapundich M, Tisdale JF, Uchida N. Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies. Cell Stem Cell. 2021;28(2):191-208.
Métais J-Y, Doerfler PA, Mayuranathan T, Bauer DE, Fowler SC, Hsieh MM, Katta V, Keriwala S, Lazzarotto CR, Luk K, et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 2019;3(21):3379-3392.
Demirci S, Mora JJHaro, Yapundich M, Drysdale C, Gamer J, Nassehi T, Bonifacino AC, Krouse AE, Linde NS, Donahue RE, et al. Fetal hemoglobin (HbF) and F-cell variance in mobilized CD34 cell transplanted rhesus monkeys. Exp Hematol. 2019.
Demirci S, Khan MBN, Hinojosa G, Le A, Leonard A, Essawi K, Gudmundsdottir B, Liu X, Zeng J, Inam Z, et al. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models. Cytotherapy. 2024.
Leonard A, Sharma A, Uchida N, Stroncek D, Panch SR, West K, Molloy E, Hughes TE, Hauffe S, Taylor T, et al. Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Adv. 2021;5(9):2403-2411.
Uchida N, Hsieh MM, Platner C, Saunthararajah Y, Tisdale JF. Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. PLoS One. 2014;9(8):e104022.
Demirci S, Leonard A, Haro-Mora JJ, Uchida N, Tisdale JF. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges. Adv Exp Med Biol. 2019.
Haro-Mora JJ, Uchida N, Demirci S, Wang Q, Zou J, Tisdale JF. Biallelic correction of sickle cell disease-derived iPSCs confirmed at the protein level through serum-free iPS-sac/erythroid differentiation. Stem Cells Transl Med. 2020.
Demirci S, Zeng J, Wu Y, Uchida N, Shen AH, Pellin D, Gamer J, Yapundich M, Drysdale C, Bonanno J, et al. BCL11A enhancer edited hematopoietic stem cells persist in rhesus monkeys without toxicity. J Clin Invest. 2020.
Furstenau D, Peer CJ, Hughes TE, Uchida N, Tisdale J, O Hall M, Figg WD, Hsieh M. Alemtuzumab Clearance, Lymphocyte Count, and T-Cell Chimerism After Hematopoietic Stem Cell Transplant in Sickle Cell Disease. Pharmacotherapy. 2021.